Posts

Axalta innovation featured image

Axalta Wins Globally Distinguished Innovation Award

Axalta, whose 175,000 square-foot Global Innovation Center is located at the Navy Yard, recently won a major globally distinguished award for innovation. The Business Intelligence Group presented Axalta with the 2023 BIG Innovation Award for its AquaEC® Flex Broad Bake Electrocoat product.

The BIG Innovation Awards recognize organizations and people who bring new ideas to life. Whether that idea is big or small, these ideas change the way we experience the world.

Axalta’s AquaEC® Flex, helps enable mass production of electric vehicles by providing extreme corrosion protection for batteries and complex vehicle designs.

“Axalta is proud to receive this award that further demonstrates our ongoing product innovation and performance,” said Robert Roop, Axalta’s Chief Technology Officer. “We are constantly innovating for our customers. The increased demand for electric vehicles drove the need for a more sustainable e-coat that applies with uniform thickness over complex vehicle designs while maintaining manufacturing productivity. Our innovation ensures that critical parts that carry and protect battery packs are heat-cured with the rest of the body frame, enabling automakers to co-produce electric vehicles and internal combustion vehicles on the same manufacturing line.”

Read the full press release on Axalta’s website.

Axalta innovation award

CCPlan timeline

PIDC Embarks on the Navy Yard Connected Community Plan and Wants Your Input

PIDC is excited to announce the embarkment on the next chapter of development for the Navy Yard’s future. PIDC and its consultant, AECOM, will collaborate with everyone in the Philadelphia community – including you! – to develop the Navy Yard Connected Community Plan, a strategic plan that will connect businesses, employees, visitors, and future residents through innovative initiatives, technologies, resources, and amenities.

Read more

Rendering of Adaptimmune's new  U.S. headquarters, designed by DIGSAU

Adaptimmune Growth Leads to Long-Term Expansion Plans in Philadelphia at The Navy Yard

Adaptimmune Therapeutics plc. (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced plans to locate its U.S. headquarters and clinical operations in a newly developed facility to be constructed at The Navy Yard in Philadelphia. The 47,400 square foot facility, located at 351 Rouse Boulevard in The Navy Yard’s Corporate Center, will house a state-of-the-art cGMP manufacturing facility designed to support the clinical development and initial commercialization of the Company’s novel engineered immunotherapies for cancer.  Read more